Spectral Diagnostics Inc.

Presenter: Paul Walker, CEO

Company Information

Company Type: Diagnostics

Development Stage: Public

Company Profile

Spectral (TSX: SDI)
Spectral is a leader in the battle against sepsis. Spectrals lead product is its Endotoxin Activity Assay (EAA), the only FDA cleared assay for the measurement of endotoxin. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream. Toraymyxin has been used on more than 70,000 patients to date, primarily in Europe and Japan, for the treatment of severe sepsis and has demonstrated a significant reduction in the mortality of patients with severe sepsis compared to standard of care.
Spectral will seek FDA approval for Toraymyxin and intends to commercialize the product together with EAA. Spectrals received approval of its Investigational Device Exemption (IDE) from the U.S. FDA in Q1 2010 and the Company expects to initiate its U.S. pivotal trial in Q2 2010.

Presenter Bio

Dr. Paul Walker, CEO
Dr. Walker left the position of COO of the Toronto General Hospital to join Spectral Diagnostics Inc. as President and CEO in April 2001.
Previously, Dr. Walker was Surgeon in Chief and Vice President of the Surgical Directorate of the University Hospital Network. Dr. Walker was an active Vascular Surgeon and the Director of the Intensive Care Program, and Professor of Medicine and Laboratory Medicine at the University of Toronto.

Dr. Walker received his M.D. from the University of Western Ontario, his Ph.D from the Salgrenska University of Göteborg Sweden, and is the author of over 100 scientific publications. Dr. Walker is a graduate of the Advanced Management Program from Harvard School of Business. 

Contact

Spectral Diagnostics Inc.
135 The West Mall
Toronto
ON, Canada
M9C 1C2

ph: 416-626-3233
fx: 416-626-1798

www.spectraldiagnostics.com
pwalker@spectraldx.com